drugset
Drugs / Cell therapy protocol 1
last change Dec 2020 re-read 3 minutes ago

Cell therapy protocol 1

Cell therapy

Developed for
COVID-19
Investigated by
Royan Institute · Shahid Beheshti University of Medical Sciences · Tehran University of Medical Sciences

Trials 1

today NCT04366063 · Ph 2/3
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT04366063 Apr → Jun 2020 COVID-19 Royan Institute Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Cell therapy protocol 1 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04366063 ↗
Modality Cell therapy “Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome” NCT04366063 ↗
Route Intravenous “Patients will receive two doses of MSCs 100×10e6 (±10%), at Day 0 and Day 2 intravenously.” NCT04366063 ↗